Clinical Trials Logo

Clinical Trial Summary

At fertilization, the binding of sperm to the zona pellucida induces the acrosome reaction releasing lytic enzymes that facilitate the passage of the sperm through the zona. The sperm then fuses with the egg's plasm membrane and enters the egg's cytoplasm. The zona pellucida, an extracellular matrix composed of three glycoproteins (ZP1, ZP2, ZP3), mediates the species-specific binding of sperm to egg. Although homologous proteins are present in mouse and humans, human sperm will not bind to the mouse zona pellucida and when the zona pellucida is experimentally removed, human sperm will not bind or fuse to the mouse egg's plasm membrane. We have created transgenic mouse lines that express one or more human zona proteins. We wish to determine if human sperm will bind to these chimeric zonae and if this binding will induce the human sperm acrosome reaction. Sperm and devitalized eggs will be collected by collaborating institution(s) under protocols and consent forms approved by that institution's IRB. Only procedures already being performed on subjects for diagnostic or treatment purposes will be used.


Clinical Trial Description

At fertilization, the binding of sperm to the zona pellucida induces the acrosome reaction releasing lytic enzymes that facilitate the passage of the sperm through the zona. The sperm then fuses with the egg s plasma membrane and enters the egg s cytoplasm. The zona pellucida, an extracellular matrix composed of three or four glycoproteins, mediates the species-specific binding of sperm to egg. Although homologous proteins are present in mouse and humans, human sperm will not bind to the mouse zona pellucida and when the zona pellucida is experimentally removed, human sperm will not bind or fuse to the mouse egg's plasma membrane. We have established transgenic mouse lines that express one or more human or rat zona proteins. We wish to determine if human sperm will bind to these chimeric zonae and if this binding will induce the human sperm acrosome reaction. Sperm and devitalized eggs will be collected by collaborating institution(s) under protocols and consent forms approved by that institution's IRB. Alternatively, anonymous fertile human sperm will be obtained from a commercial sperm bank using a donor consent agreement. Only procedures already being performed on subjects for diagnostic or treatment purposes will be used. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00340587
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date May 2, 1997
Completion date February 24, 2016

See also
  Status Clinical Trial Phase
Completed NCT01558141 - Follicular Flushing N/A
Not yet recruiting NCT04519918 - Clinical Application of Artificial Oocyte Activation Technique (AOA) in ART N/A
Recruiting NCT03810001 - Mechanical Stimulation Improve the Fertilization in ICSI Cycle N/A
Not yet recruiting NCT04523103 - Artificial Assisted Activation Following in Fertilization Failure N/A
Completed NCT00598208 - A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED) Phase 2
Completed NCT02913781 - Polar Body Removal Before ICSI for Oocyte Activation in Previous Fertilization Failure Cases N/A
Recruiting NCT04537481 - Lipidic Differences of Sperm Between Normal and Low Fertilization Patients N/A
Completed NCT01223118 - Evaluation of the Impact of Vitrification on Oocytes N/A